1. An Update on PCSK9 Inhibitors

3. Program Goals

4. Support for LDL Causality in ASCVD

5. Genetics of LDL Lowering

6. Evidence For Drugs That Provide Additional LDL-C Lowering in Combination With Statins

7. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

8. Comparison of Lipid Guidelines by Society

9. 2016 ACC Expert Consensus: Role of Non-Statin Therapies in LDL-C Lowering

10. 2016 ESC/EAS Guidelines on the Management of Dyslipidemias: Treatment Goals for LDL-C

11. LDL-C: Target, Goals, and Thresholds for Non-Statin Therapy

12. Impact of a PCSK9 mAb on LDLR Expression

13. Currently Available PCSK9 Inhibitors

14. Lipid Research Clinics Coronary Primary Prevention Trial

15. Niacin: Negative Outcome Studies in Dyslipidemia

16. IMPROVE-IT

17. FOURIER: Types of Cardiovascular Outcomes

18. Comparison of FOURIER With Cholesterol Treatment Trialists’ Collaboration

19. PCSK9 Inhibitor CV Outcomes Trials

20. Alirocumab and Evolocumab: US Labeling and Indications

21. Guideline Updates on the Use of PCSK9 Inhibitors

22. Integrating Emerging Clinical Data Into Clinical Practice: An Evolving Treatment Algorithm

23. FOURIER: Safety

24. Safety of Low LDL-C: Alirocumab-Treated Patients in the Global Safety Pool

25. AACE Recommendations

26. Barrier Studies and Recommendations

27. Improving Access to PCSK9 Inhibitors

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)